Evidence map›Paper›PMID 33543138›Full record

ArticleBrain communications2021

Measuring cerebral perfusion with [

Elijah Mak, Monika Grigorova, Jessica Beresford-Webb, Maura Malpetti, Madeline Walpert, Stephanie Brown, Elizabeth Jones, Isabel Clare, Young T Hong, Tim D Fryer and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 2 countries.

Elijah MakDepartment of Psychiatry, University of Cambridge, School of Clinical Medicine, Cambridge Biomedical Campus, CB2 0QQ, UK.ORCID 0000-0002-6437-8024
Monika GrigorovaDepartment of Psychiatry, University of Cambridge, School of Clinical Medicine, Cambridge Biomedical Campus, CB2 0QQ, UK.
Jessica Beresford-WebbDepartment of Psychiatry, University of Cambridge, School of Clinical Medicine, Cambridge Biomedical Campus, CB2 0QQ, UK.
Maura MalpettiDepartment of Clinical Neurosciences, University of Cambridge, Cambridge Biomedical Campus, Cambridge, CB2 0SZ, UK.ORCID 0000-0001-8923-9656
Madeline WalpertDepartment of Psychiatry, University of Cambridge, School of Clinical Medicine, Cambridge Biomedical Campus, CB2 0QQ, UK.
Stephanie BrownDepartment of Psychiatry, University of Cambridge, School of Clinical Medicine, Cambridge Biomedical Campus, CB2 0QQ, UK.
Elizabeth JonesDepartment of Psychiatry, University of Cambridge, School of Clinical Medicine, Cambridge Biomedical Campus, CB2 0QQ, UK.
Isabel ClareDepartment of Psychiatry, University of Cambridge, School of Clinical Medicine, Cambridge Biomedical Campus, CB2 0QQ, UK.
Young T HongWolfson Brain Imaging Centre, University of Cambridge, CB2 0QQ, UK.
Tim D FryerWolfson Brain Imaging Centre, University of Cambridge, CB2 0QQ, UK.
Jonathan P ColesDivision of Anaesthesia, University of Cambridge, Cambridge, CB2 0QQ, UK.
Franklin I AigbirhioWolfson Brain Imaging Centre, University of Cambridge, CB2 0QQ, UK.
David K MenonDivision of Anaesthesia, University of Cambridge, Cambridge, CB2 0QQ, UK.
Peter J NestorQueensland Brain Institute, University of Queensland, Queensland, QLD 4072, Australia.
Anthony J HollandDepartment of Psychiatry, University of Cambridge, School of Clinical Medicine, Cambridge Biomedical Campus, CB2 0QQ, UK.
Shahid H ZamanDepartment of Psychiatry, University of Cambridge, School of Clinical Medicine, Cambridge Biomedical Campus, CB2 0QQ, UK.
University of Cambridge · GBThe University of Queensland · AU

Funding

National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)U24AG021886 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI TATIANA M. FOROUD · 2002 to 2026
$119.8M
Project 3: Biomarkers for DS Clinical TrialsU19AG068054 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI O'BRYANT, SID E · 2020 to 2025
$103.7M
NiAD Supplement WashU Start UpU01AG051406 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HANDEN, BENJAMIN L, TOGA, ARTHUR W · 2015 to 2019
$21.3M
Medical Research Council MR/K02308X/1Medical Research Council MR/M009041/1NIA NIH HHS U01 AG051406NIA NIH HHS U19 AG068054NIA NIH HHS U24 AG021886
6 · The paper itself

Abstract

Positron emission tomography imaging of glucose hypometabolism and amyloid deposition are two well-established methods to evaluate preclinical changes in Alzheimer's disease and people with Down syndrome. However, the use of both imaging modalities may overburden participants, particularly those with intellectual disabilities and cognitive impairment. The relative tracer delivery of the [

Indexed as

Alzheimer’s diseaseDown syndromeneurodegenerationperfusionpositron emission tomography

Identifiers

PMID33543138
PMCPMC7849981
OpenAlexW3095750872

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.